BHVN - NYSE

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%

HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.14B

EPS-6.8600

P/E Ratio-1.58

Earnings Date08/10/2026

-222.16%

Return on Invested Capital

17%

3Y+125.0%

5Y+60.0%

10Y-

-1418.85%

Return on Equity

610%

3Y+1240.0%

5Y+101.0%

10Y-

-163.66%

Return on Assets

19%

3Y+90.0%

5Y+54.0%

10Y-

Biohaven Ltd. Management Team

BHVN · NYSE

Dr. Vladimir Coric M.D.

Chairman & Chief Executive Officer

Compensation

$2,063,405

Born 1971(Age 55)

Mr. John Tilton

Chief Commercial Officer of Rare Diseases

Born 1968(Age 58)

male

Mr. Matthew Buten

Chief Financial Officer

Compensation

$1,097,864

Born 1961(Age 65)

male

Dr. Bruce D. Car DACVP, Ph.D.

Chief Scientific Officer

Compensation

$989,607

Born 1962(Age 64)

Mr. Warren Volles J.D.

General Counsel & Chief Legal Officer

male

Mr. Clifford Bechtold M.S.

President, GM of Biohaven Ireland & Chief Compliance Officer

male

Ms. Deb Young

Senior Director of Regulatory Affairs & Operations

female

Ms. Kimberly Gentile

Senior Vice President of Clinical Operations

Compensation

$893,500

Born 1966(Age 60)

female

Mr. George C. Clark CPA

Vice President & Chief Accounting Officer

Born 1985(Age 41)

male

Ms. Jennifer Porcelli

Vice President of Investor Relations

female

INSIDER TRANSACTIONS

Biohaven Ltd. Insider Positioning

BHVN · NYSE

During the last 12 months, insiders have purchased $30.64M worth of BHVN shares, with no selling activity reported.

3 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

3-6 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

6-9 Months

Bought

4.1M

30.64M

Sold

0.00

Net Activity

+30.6M

+$30.64M

9-12 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

Top Buyers

CJW

Childs John W

Director

3.3M shares•1 transactions

$25.00M

Bailey Gregory

Director

400.0K shares•1 transactions

$3.00M

Coric Vlad

Director, Officer: Chief Executive Officer

333.3K shares•1 transactions

$2.50M

CGC

Clark George C.

Officer: Vp, Chief Accounting Officer

17.0K shares•1 transactions

$145K

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $30.64M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

∞:1

Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.

Insider Participation

High Buying

4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.

Insider Activity Insight

Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.

SEC PROXY FILINGS

SEC Filings

BHVN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	March 13, 2026	April 28, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	March 18, 2025	May 05, 2025	2025	View Filing
DEF 14A DEF 14A 2024 N/A	March 18, 2024	April 30, 2024	2024	View Filing
DEF 14A DEF 14A 2023 N/A	March 23, 2023	May 02, 2023	2023	View Filing

Showing 1 to 4 of 4 filings

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.